A scoping review and network meta-analysis for efficacy and safety of glaucoma medication in Japanese patients
ConclusionThe efficacy and safety of glaucoma medications were assessed by NMA as reference to those of timolol maleate 0.5% in Japanese patients. PG analogs were the most efficacious in reducing IOP. However, PG analogs were also associated with higher rates of adverse reactions and conjunctival hyperemia. (Source: Japanese Journal of Ophthalmology)
Source: Japanese Journal of Ophthalmology - February 24, 2020 Category: Opthalmology Source Type: research

Effects of a prostaglandin F2alpha derivative glaucoma drug on EGF expression and E-cadherin expression in a corneal epithelial cell line.
Conclusions: Travoprost activates epithelial cell proliferation by up-regulating an EGF-related signal in association with the suppression of E-cadherin localization in the cell-cell contact zone. Modulation of the EGF signal may be a strategy to minimize the negative impact of this mitogen on reformation of corneal barrier function during epithelial renewal. PMID: 31986917 [PubMed - as supplied by publisher] (Source: Cutaneous and Ocular Toxicology)
Source: Cutaneous and Ocular Toxicology - January 27, 2020 Category: Toxicology Authors: Takada Y, Yamanaka O, Okada Y, Sumioka T, Reinach PS, Saika S Tags: Cutan Ocul Toxicol Source Type: research

Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase After Cataract Surgery in Eyes With Glaucoma
Dr Özcura raised several questions regarding our article on the effect of topical hypotensive medications to prevent an increase in intraocular pressure (IOP) after cataract surgery in eyes with glaucoma.1 Our study revealed that, compared with travoprost or timolol, brinzolamide administered to eyes with glaucoma immediately after phacoemulsification more effectively decreases the short-term IOP increase. We would like to address the questions raised by Dr Özcura. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - December 9, 2019 Category: Opthalmology Authors: Ken Hayashi, Motoaki Yoshida, Tatsuhiko Sato, Shin-ichi Manabe Tags: Correspondence Source Type: research

Reply to Comment on: Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase After Cataract Surgery in Eyes With Glaucoma
Dr Özcura raised several questions regarding our article on the effect of topical hypotensive medications to prevent an increase in intraocular pressure (IOP) after cataract surgery in eyes with glaucoma.1 Our study revealed that, compared with travoprost or timolol, brinzolamide administered to eyes with glaucoma immediately after phacoemulsification more effectively decreases the short-term IOP increase. We would like to address the questions raised by Dr Özcura. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - December 9, 2019 Category: Opthalmology Authors: Ken Hayashi, Motoaki Yoshida, Tatsuhiko Sato, Shin-ichi Manabe Tags: Correspondence Source Type: research

Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
AbstractPurposeTo assess the ocular hypotensive effect of 15-keto fluprostenol, the oxidized metabolite of travoprost, on glaucoma patients, through a randomized double-masked placebo-controlled study.MethodsTwelve patients with ocular normal tension glaucoma (NTG) (intraocular pressure [IOP]  
Source: International Ophthalmology - December 3, 2019 Category: Opthalmology Source Type: research

Effect of 6-week washout period on intraocular pressure following chronic prostaglandin analogue treatment: a randomized controlled trial.
Abstract OBJECTIVE: To evaluate the effect of a 6-week washout period on intraocular pressure (IOP) following long-term monotherapy prostaglandin use. DESIGN: Prospective, randomized, controlled, single-centre, single-blinded, parallel-group clinical study. PARTICIPANTS: Subjects aged>18 years diagnosed with open-angle glaucoma or open-angle glaucoma suspects based on elevated IOP in one or both eyes, using monotherapy topical latanoprost, bimatoprost, or travoprost once daily. METHODS: Subjects were prospectively randomized to continue prostaglandin analogue (PGA) monotherapy (control group) or ...
Source: Canadian Journal of Ophthalmology - November 7, 2019 Category: Opthalmology Authors: Lim CW, Diaconita V, Liu E, Ault N, Lizotte D, Nguyen M, Hutnik CML Tags: Can J Ophthalmol Source Type: research

Evaluation of Contrast sensitivity after four different treatment modalities using optec-functional vision analyzer in primary open-angle glaucoma
CONCLUSION: Our study showed that CS values at low and high spatial frequencies after applying timolol and brimonidine eye drops are temporarily reduced in patients with POAG. (Source: Middle East African Journal of Ophthalmology)
Source: Middle East African Journal of Ophthalmology - August 26, 2019 Category: Opthalmology Authors: Parvin Azizzadeh Masoud Safarzadeh Source Type: research

Comment on: Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase after Cataract Surgery in Eyes with Glaucoma
We read with great interest the randomized controlled trial evaluating the prophylactic effect of the classes of topical intraocular pressure (IOP) –lowering medication for preventing IOP increase after cataract surgery in eyes with glaucoma.1 Hayashi and associates1 found that the mean IOP and incidence of IOP spikes were significantly lower in patients who were given postoperative brinzolamide compared with travoprost or timolol. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - August 2, 2019 Category: Opthalmology Authors: Arij Daas, Henrietta Ho, Kin Sheng Lim Tags: Correspondence Source Type: research

Efficacy of travoprost for the treatment of patients with glaucoma
Conclusion: The findings of the present study will summarize the updated evidence of travoprost for patients with glaucoma. PROSPERO registration number: PROSPERO CRD42019126956. (Source: Medicine)
Source: Medicine - July 1, 2019 Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research

Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: A meta-analysis
Conclusions: 0.03% bimatoprost appears more effective following long time use (3 and 6 month post-treatment) for IOP control compared to 0.005% latanoprost, and is more effective compared to 0.004% travoprost after being used for a certain period of time (3 months post-treatment); nevertheless, 0.005% latanoprost is better tolerated in patients with POAG or OHT. (Source: Medicine)
Source: Medicine - July 1, 2019 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

Prospective randomized clinical trial on the effects of latanoprost, travoprost and bimatoprost on latanoprost non-responders.
CONCLUSION: There is no added benefit of switching latanoprost to another topical prostaglandin for patients who are initially non-responders. Regression towards the mean and the Hawthorne effect are probably important factors explaining the additional IOP reduction obtained after randomization and explain the result of most switch studies. PMID: 31164290 [PubMed - as supplied by publisher] (Source: Journal Francais d Ophtalmologie)
Source: Journal Francais d Ophtalmologie - June 6, 2019 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

Randomized crossover trial comparing effectiveness and tolerability of generic and brand-name travoprost.
Abstract OBJECTIVE: The primary goal is to determine if the intraocular pressure reducing effect of generic Sandoz travoprost is equivalent to that of brand-name Travatan Z. The secondary goal is to determine if generic Sandoz travoprost is as well tolerated as Travatan Z. METHODS: This prospective randomized crossover trial allocated 76 patients with primary open-angle glaucoma, normotensive glaucoma, or ocular hypertension in a 1:1 ratio to start with either generic Sandoz travoprost or Travatan Z. Crossover happened after 3 weeks. The primary endpoint, intraocular pressure, was measured in both eyes at bas...
Source: Canadian Journal of Ophthalmology - April 1, 2019 Category: Opthalmology Authors: Ta Kim D, Daigle P, Carbonneau M Tags: Can J Ophthalmol Source Type: research

Effects of anti-glaucoma prostaglandin ophthalmic solutions on cultured human corneal epithelial cells.
CONCLUSIONS: Xalatan and Lumigan 0.01% ophthalmic solutions demonstrated potent cytotoxicity compared with Lumigan 0.03%, Travatan, Taflotan and Taflotan UD. Taflotan UD, compared to Taflotan 0.0015%, induced less oxidative stress and apoptotic signalling. The cytotoxicity might be partly associated with benzalkonium chloride. PMID: 30884982 [PubMed - as supplied by publisher] (Source: Current Eye Research)
Source: Current Eye Research - March 18, 2019 Category: Opthalmology Authors: Tong L, Matsuura E, Takahashi M, Nagano T, Kawazu K Tags: Curr Eye Res Source Type: research

New insights in vitiligo treatments using bioactive compounds from Piper nigrum.
This study shows that Piper nigrum (PN) extract and its main alkaloid, piperine, promote melanocyte proliferation in vivo, being consistent with previous study. A PN fruit extract and pure piperine were integrated in two different ointments and tested on human subjects affected by vitiligo. A number of 9 areas were treated: 3 using the extract, 3 using pure piperine, 1 using travoprost solution, and 2 using an association of travoprost (prostaglandin F2α analogue) solution and our products. Pigmentation was achieved in all the treated areas. The extract caused faster and more remarkable results than the pure piperine...
Source: Experimental and Therapeutic Medicine - January 28, 2019 Category: General Medicine Tags: Exp Ther Med Source Type: research

Variation in Prostaglandin Analog Prices Paid for Through Medicare Part D
Conclusions: There is substantial variation in PGA prices when purchased by Medicare Part D enrollees across the United States and within each state itself. Simultaneously, the prices and total expenditure on these medications are increasing yearly. Physicians should be cognizant of this price variation for these expensive and chronically used drugs and should educate patients to optimize their Part D supplemental plan. (Source: Journal of Glaucoma)
Source: Journal of Glaucoma - December 28, 2018 Category: Opthalmology Tags: Online Articles: Brief Report Source Type: research

In vitro effects of benzalkonium chloride and prostaglandins on human meibomian gland epithelial cells.
CONCLUSIONS: BAC showed cytotoxic effects on HMGECs starting with a concentration of 0.1μg/ml. The combination of BAC and prostaglandin-analogs might have a synergistic effect which results in higher toxicity than BAC alone. Unpreserved eye drops and eye drops preserved with Polyquaternium-1 are less damaging to HMGECs. PMID: 30580056 [PubMed - as supplied by publisher] (Source: Annals of Anatomy)
Source: Annals of Anatomy - December 20, 2018 Category: Anatomy Authors: Rath A, Eichhorn M, Träger K, Paulsen F, Hampel U Tags: Ann Anat Source Type: research

Washout Duration of Prostaglandin Analogues: A Systematic Review and Meta-analysis.
Conclusion: A significant IOP-lowering effect of latanoprost was not observed beyond 4 weeks, suggesting this may be an appropriate washout period for latanoprost. We could not identify appropriate washout periods for either travoprost or bimatoprost, although a majority of articles had 4-week washout durations for the two drugs. Despite the widespread use of this class of medication, there is a paucity of literature on the effects of PGA washout in patients that are treatment naïve to other topical medications. PMID: 30363694 [PubMed] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - October 28, 2018 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues.
CONCLUSION: Overall, this study suggests a better subjective and objective ocular tolerance when patients were treated with preservative-free latanoprost than with other preserved prostaglandin analogues monotherapy. Switching to preservative-free latanoprost maintained intraocular pressure at the same level as preservative prostaglandin analogue, but improved ocular surface tolerance. PMID: 30301370 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - October 10, 2018 Category: Opthalmology Authors: El Ameen A, Vandermeer G, Khanna RK, Pisella PJ Tags: Eur J Ophthalmol Source Type: research

Experimental Evaluation of Travoprost-Induced Changes in Biomechanical Behavior of Ex-Vivo Rabbit Corneas.
CONCLUSIONS: Significant reductions in corneal stiffness, that are associated with the use of travoprost, were observed experimentally under low applied stresses. This stiffness-reduction effect should be considered in clinical management, especially in primary open angle glaucoma treatment. PMID: 30273056 [PubMed - as supplied by publisher] (Source: Current Eye Research)
Source: Current Eye Research - October 1, 2018 Category: Opthalmology Authors: Zheng X, Wang Y, Zhao Y, Cao S, Zhu R, Huang W, Yu A, Huang J, Wang Q, Wang J, Bao F, Elsheikh A Tags: Curr Eye Res Source Type: research

The Effect of Prostaglandin Analogues on the Ciliary Zonular Fibers of the Rabbit Crystalline Lens.
CONCLUSIONS: PG analogues may induce zonular change in rabbits microscopically. There was no association between zonular changes and the levels of certain types of MMP or TIMP in the aqueous humor or crystalline lens after topical treatment with PG analogues. PMID: 30015523 [PubMed - as supplied by publisher] (Source: Current Eye Research)
Source: Current Eye Research - July 17, 2018 Category: Opthalmology Authors: Hwang HB, Kim SY Tags: Curr Eye Res Source Type: research

Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients.
Authors: El Hajj Moussa WG, Farhat RG, Nehme JC, Sahyoun MA, Schakal AR, Jalkh AE, Abi Karam MP, Azar GG Abstract Aim: The purpose of this study is to evaluate and compare the efficacy of 4 prostaglandin analogues (PGAs) and to determine the incidence of ocular surface disease in newly diagnosed, primary open-angle glaucoma (POAG) patients started on one of those 4 PGAs: bimatoprost (benzalkonium chloride, BAK, 0.3 mg/mL), latanoprost (BAK 0.2 mg/mL), travoprost (polyquad), and tafluprost (BAK-free). Patients and Methods: In this single-center, open-label trial, 32 patients newly diagnosed with PO...
Source: Journal of Ophthalmology - May 2, 2018 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Association of Postoperative Topical Prostaglandin Analog or Beta-Blocker Use and Incidence of Pseudophakic Cystoid Macular Edema
Conclusions: To the best of our knowledge this is the largest study that has investigated the association between postoperative topical PGA or topical beta-blocker use and the incidence of pseudophakic CME. Postoperative use of both topical PGAs and topical beta-blockers was found to be associated with the incidence of pseudophakic CME. (Source: Journal of Glaucoma)
Source: Journal of Glaucoma - May 1, 2018 Category: Opthalmology Tags: Original Studies Source Type: research

Meibomian Gland Features and Conjunctival Goblet Cell Density in Glaucomatous Patients Controlled With Prostaglandin/Timolol Fixed Combinations: A Case Control, Cross-sectional Study
Purpose: To investigate, using in vivo confocal microscopy (IVCM), the Meibomian gland (MG) features and conjunctival goblet cell density (GCD) in glaucomatous patients controlled with prostaglandin/timolol fixed combinations (PTFCs). Materials and Methods: In this cross-sectional study, 60 white patients were treated with PTFCs, 15 with latanoprost+timolol (L+T) unfixed combination, and 15 controls were enrolled. Patients underwent the Ocular Surface Disease Index questionnaire, tear film breakup time, corneal staining, Schirmer test I, and IVCM of MGs and goblet cells. The main outcome measures were: mean Meibomian ...
Source: Journal of Glaucoma - April 1, 2018 Category: Opthalmology Tags: Original Studies Source Type: research

Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario.
Abstract Medication cost for the same indication can vary considerably and can affect patient compliance. In this comparative cost analysis of commonly prescribed ophthalmology medications, the differences in cost between generic and brand name medications as well as different medications within an individual drug class were evaluated. Eye preparations from the Ontario Drug Benefit Formulary were identified, and further agents commonly prescribed by ophthalmologists were included. The standardized prescription drug cost, which includes the cost of the medication, mark-up, and dispensing cost, was provided by Ontar...
Source: Canadian Journal of Ophthalmology - April 1, 2018 Category: Opthalmology Authors: Popovic M, Chan C, Lattanzio N, El-Defrawy S, Schlenker MB Tags: Can J Ophthalmol Source Type: research

Reversal of retinal pigment epithelial detachment after cessation of topical travoprost therapy
ConclusionHence, clinicians should be aware of this rare incidence of RPED followed by travoprost therapy. First case of RPED following travoprost therapy and complete reattachment upon withdrawal is reported here in this case report. (Source: International Ophthalmology)
Source: International Ophthalmology - March 22, 2018 Category: Opthalmology Source Type: research

Prospective Evaluation of Two iStent ® Trabecular Stents, One iStent Supra ® Suprachoroidal Stent, and Postoperative Prostaglandin in Refractory Glaucoma: 4-year Outcomes
ConclusionIOP control was achieved safely with two trabecular micro-bypass stents, one suprachoroidal stent, and postoperative prostaglandin. This microinvasive, ab interno approach introduces a possible new treatment option for refractory disease.Trial RegistrationNCT01456390.FundingGlaukos Corporation. (Source: Advances in Therapy)
Source: Advances in Therapy - February 23, 2018 Category: Drugs & Pharmacology Source Type: research

Periorbital Changes associated with Topical Prostaglandins Analogues in a Hispanic Population.
CONCLUSION: QOL questionnaire showed that Bimatoprost side effects had the most negative impact in QOL, followed by the Latanoprost and Travoprost groups. PMID: 29220066 [PubMed - in process] (Source: Puerto Rico Health Sciences Journal)
Source: Puerto Rico Health Sciences Journal - December 9, 2017 Category: International Medicine & Public Health Tags: P R Health Sci J Source Type: research

A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension
Conclusions This study found travoprost to be noninferior to timolol in lowering IOP in patients with pediatric glaucoma or ocular hypertension. Travoprost was well-tolerated, and no treatment-related systemic adverse events were reported. (Source: Journal of American Association for Pediatric Ophthalmology and Strabismus)
Source: Journal of American Association for Pediatric Ophthalmology and Strabismus - September 6, 2017 Category: Opthalmology Source Type: research

A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension
To evaluate efficacy and safety of travoprost in pediatric patients with ocular hypertension or glaucoma and demonstrate its noninferiority to timolol. (Source: Journal of AAPOS)
Source: Journal of AAPOS - September 5, 2017 Category: Opthalmology Authors: El Roy Dixon, Theresa Landry, Subha Venkataraman, Nancy Gustafson, Craig Salem, Yasmin Bradfield, Leyla Ali Aljasim, Robert Feldman Source Type: research

Inadvertent Cyclodialysis Cleft and Hypotony Following Ab-Interno Trabeculotomy Using the Trabectome Device Requiring Surgical Repair
Conclusions: Inadvertent cyclodialysis cleft from a malpositioned AIT and resultant hypotony is rare and in this case was successfully treated by direct suture cyclopexy. (Source: Journal of Glaucoma)
Source: Journal of Glaucoma - August 1, 2017 Category: Opthalmology Tags: Case Report/Small Case Series Source Type: research

The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP
AbstractPurposeTo evaluate the effect of bimatoprost/timolol maleate fixed combination (BTFC), latanoprost/timolol maleate fixed combination (LTFC), and travoprost/timolol maleate fixed combination (TTFC) on 24-h intraocular pressure (IOP) in patients with open-angle glaucoma.MethodsThis prospective, observer-masked, randomized study included 50 patients with primary open-angle glaucoma. All patients were using hypotensive lipids and timolol maleate fixed combination treatment for ≥4 weeks and had an IOP ≤ 21 mmHg. Group 1 (n = 18) received BTFC, group 2 (n = 14) received LTFC,...
Source: International Ophthalmology - June 14, 2017 Category: Opthalmology Source Type: research

Travoprost/timolol
(Source: Reactions Weekly)
Source: Reactions Weekly - June 1, 2017 Category: Drugs & Pharmacology Source Type: research

Blood Pressure Elevation Associated with Topical Prostaglandin F2 α Analogs: An Analysis of the Different Spontaneous Adverse Event Report Databases.
The objective of this study was to evaluate the association between topical PGF2α analogs and blood pressure elevation. We analyzed the reports obtained from the Food and Drug Administration Adverse Event Reporting System (FAERS) database from the first quarter of 2004 until the end of 2015 and the Japanese Adverse Drug Event Report (JADER) database from April 2004 to January 2016 for signal detection using reporting odds ratio (ROR), a method of disproportionality analyses. Signals are considered significant if the ROR estimates and lower bound of the 95% confidence interval (CI) exceed 1. Preferred terms in the Med...
Source: Biological and Pharmaceutical Bulletin - May 2, 2017 Category: Drugs & Pharmacology Authors: Ohyama K, Kawakami H, Inoue M Tags: Biol Pharm Bull Source Type: research

Implantation of two second ‐generation trabecular micro‐bypass stents and topical travoprost in open‐angle glaucoma not controlled on two preoperative medications: 18‐month follow‐up
Conclusions and RelevanceIn OAG eyes on 2 preoperative medications, treatment with 2 second‐generation trabecular stents and 1 postoperative prostaglandin resulted in mean IOP ≤13 mmHg with reduction of 1 medication, with favorable safety. These findings show the utility of second‐generation trabecular bypass with postoperative prostaglandin in patients with OAG. (Source: Clinical and Experimental Ophthalmology)
Source: Clinical and Experimental Ophthalmology - April 1, 2017 Category: Opthalmology Authors: John Berdahl, Lilit Voskanyan, Jonathan S Myers, Dana M Hornbeak, Jane Ellen Giamporcaro, L Jay Katz, Thomas W Samuelson Tags: Original Article Source Type: research

Efficacy and Tolerability of Travoprost 0.004%/Timolol 0.5% Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy.
Authors: Lerner SF, Park KH, Hubatsch DA, Erichev V, Paczka JA, Roberts TV Abstract Objective. To evaluate the efficacy and tolerability of travoprost 0.004%/timolol 0.5% fixed-dose combination (TTFC) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) inadequately controlled on beta-blocker monotherapy. Methods. In this phase IV, open-label study, 156 patients on beta-blocker monotherapy with mean intraocular pressure (IOP) between 18 and 32 mmHg were randomized (no washout period) to receive TTFC for 8 weeks (TTFC group) or to continue beta-blocker monotherapy for 4 weeks followed by TT...
Source: Journal of Ophthalmology - February 28, 2017 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Sustained drug delivery for glaucoma: current data and future trends
Purpose of review:Sustained drug delivery has been recognized as a need for patients with ocular hypertension or glaucomatous optic neuropathy. Several sustained drug delivery systems and devices are currently on the horizon. This review aims to summarize initial results with these platforms, as reported in the literature, and also provide insight into their possible role in the glaucoma treatment paradigm. Recent findings:Sustained drug delivery systems currently on the horizon include the topical bimatoprost ocular insert, travoprost and latanoprost punctal plugs, latanoprost-eluting contact lenses, bimatoprost and trav...
Source: Current Opinion in Ophthalmology - February 28, 2017 Category: Opthalmology Tags: GLAUCOMA: Edited by Donald L. Budenz Source Type: research

Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma
Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - February 24, 2017 Category: Opthalmology Source Type: research

The effects of selective laser trabeculoplasty and travoprost on circadian intraocular pressure fluctuations: A randomized clinical trial
Background: To compare the effect of selective laser trabeculoplasty (SLT) and travoprost on 24-hour IOP fluctuations in primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG). Methods: Sixty eyes were included. Sixteen and 14 eyes of POAG patients were randomized to receive 360° SLT or 0.004% travoprost, respectively. Fourteen and 16 eyes of NTG patients were randomized to receive either SLT or travoprost, respectively. The 24-hour IOP data were collected before treatment and 6 to 8 weeks after treatment. IOP was measured at 2 hours intervals in the sitting position during daytime (9 AM to 7 PM) and i...
Source: Medicine - February 1, 2017 Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research

Molecules, Vol. 22, Pages 217: A Novel Convergent Synthesis of the Potent Antiglaucoma Agent Tafluprost
Tafluprost (AFP-168, 5) is a unique 15-deoxy-15,15-difluoro-16-phenoxy prostaglandin F2 α (PGF2α) analog used as an efficacious ocular hypotensive agent in the treatment of glaucoma and ocular hypertension, as monotherapy, or as adjunctive therapy to β-blockers. A novel convergent synthesis of 5 was developed employing Julia–Lythgoe olefination of the structurally advanced prostag landin phenylsulfone 16, also successfully applied for manufacturing of pharmaceutical grade latanoprost (2), travoprost (3) and bimatoprost (4), with an aldehyde ω-chain synthon 17. The use of the same prostaglandin ...
Source: Molecules - January 31, 2017 Category: Chemistry Authors: Ma łgorzata Krupa Micha ł Chodyński Anna Ostaszewska Piotr Cmoch Iwona Dams Tags: Article Source Type: research

Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: a Randomized Trial
To assess adherence to treatment with fixed-combination travoprost 0.004%/timolol 0.5% (TTFC) compared with separate containers of travoprost 0.004% and timolol 0.5% (TRAV+TIM; unfixed) using electronic dosing aids (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - December 16, 2016 Category: Opthalmology Authors: Howard S. Barnebey, Alan L. Robin Tags: Original Articles Source Type: research

Efficacy and patient tolerability of preservative ‐free latanoprost compared with preservative prostaglandin analogs in patients with ocular hypertension or glaucoma
ConclusionsThese preliminary results show that PF latanoprost has better subjective and objective local tolerance than preservative PGA. Switching to PF latanoprost seems to maintain IOP at the same level as preservative PGA but improve ocular surface toxicity. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - September 14, 2016 Category: Opthalmology Authors: A. El Ameen, G. Vandermeer, P.J. Pisella Tags: Abstracts from the 2016 European Association for Vision and Eye Research Conference Source Type: research

Prolonged Ocular Inflammation in Endotoxin-Induced Uveitis in Lysosomal Phospholipase A2-Deficient Mice.
Abstract PURPOSE: The goal of present study was to elucidate the pathophysiological roles of lysosomal phospholipase A2 (LPLA2) in intraocular pressure (IOP) levels and ocular inflammation. METHODS: C57BL/6 (wild-type) and LPLA2-deficient mice with C57BL/6 background were employed. The IOPs were compared between wild-type and LPLA2-deficient mice during their aging, after topical administration of antiglaucoma medications such as travoprost, dorzolamide, or timolol maleate, or after induction of endotoxin-induced uveitis (EIU) using lipopolysaccharide (LPS). Concerning the EIU, ocular inflammation was also ev...
Source: Current Eye Research - September 9, 2016 Category: Opthalmology Authors: Sawada K, Hiraoka M, Abe A, Kelly R, Shayman JA, Ohguro H Tags: Curr Eye Res Source Type: research

Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term?
AbstractThe purpose of the study is to assess the changes in the long-term effects of prostaglandin analogues (PGAs) on intraocular pressure (IOP) reduction in patients with primary open-angle glaucoma (POAG). Data of POAG patients treated with latanoprost (0.005  %), travoprost (0.004 %), or bimatoprost (0.03 %) as the first line treatment for 5 years or more were retrospectively evaluated. Baseline ophthalmic assessment values were recorded together with the IOP at the 6th month, 1st year, and then annually. The 79 patients included 33 (41.8 %) men an d 46 (58.2 %) women. There were 34 (43.0...
Source: International Ophthalmology - August 9, 2016 Category: Opthalmology Source Type: research

Effect of Travoprost and Nonsteroidal Anti-Inflammatory Drug on Diurnal Intraocular Pressure in Normal Subjects with Low-Teen Baseline Intraocular Pressure
Journal of Ocular Pharmacology and Therapeutics Jul 2016, Vol. 32, No. 6: 365-370. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - July 15, 2016 Category: Opthalmology Authors: Rei SakataToshihiro SakisakaHiroshi MatsuoKazunori MiyataMakoto Aihara Source Type: research

Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost
Purpose: To assess the effect of switching 1 eye to topical travoprost 0.004% preserved with SofZia (TRAVATAN Z solution) in patients who had chronic superficial punctate keratitis (SPK) in both eyes treated with benzalkonium chloride–preserved latanoprost 0.005% (XALATAN). Methods: This was a prospective, randomized, controlled, multicenter, open-label, comparative 3-month follow-up study. Patients with open-angle glaucoma or ocular hypertension who received XALATAN monotherapy for at least 3 months and had SPK in both eyes were enrolled at 9 facilities. For each patient, 1 eye was randomly selected and switched to...
Source: Journal of Glaucoma - June 1, 2016 Category: Opthalmology Tags: Online Articles: Original Studies Source Type: research

Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension
In conclusion, BAK-preserved tafluprost ophthalmic solution 0.0015 % remains a useful option for the treatment of Asian patients with glaucoma and ocular hypertension. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - May 25, 2016 Category: Drugs & Pharmacology Source Type: research

Comparison of Latanoprost, Travoprost, and Bimatoprost on Adherence, Persistence, and Pattern of Initial Therapy in Glaucoma and Ocular Hypertension: An Administrative Claims Database Analysis
Glaucoma causes an atrophy of the optic nerve with increased intraocular pressure (IOP), which can lead to blindness. When topical treatment fails to lower IOP adequately, the patient may add or change medications or have surgery/laser treatment. Prostaglandin therapy is recommended as initial therapy. The purpose of this study was to compare medication adherence, persistence, and post-index patterns between latanoprost, bimatoprost, and travoprost as initial therapies for glaucoma/ocular hypertension. (Source: Value in Health)
Source: Value in Health - May 1, 2016 Category: Global & Universal Authors: JH Heo, KL Rascati Tags: SENSORY SYSTEMS DISORDERS – Patient-Reported Outcomes & Patient Preference Studies Source Type: research

Prostaglandins in the eye: Function, expression, and roles in glaucoma.
Authors: Doucette LP, Walter MA Abstract Prostaglandins are small pro-inflammatory molecules derived from arachidonic acid that play roles in a multitude of biological processes including, but not limited to, inflammation, pain modulation, allergies, and bone formation. Prostaglandin analogues are the front-line medications for the treatment of glaucoma, a condition resulting in blindness due to the death of retinal ganglion cells. These drugs act by lowering intraocular pressure (IOP), a major risk factor for glaucoma. The currently used prostaglandin analogues (latanoprost, bimatoprost, tafluprost, and travoprost...
Source: Ophthalmic Genetics - April 15, 2016 Category: Opthalmology Tags: Ophthalmic Genet Source Type: research

Prostaglandin analogues: current treatment option for glaucoma
Abstract Glaucoma is a progressive optic neuropathy and is the world’s second leading cause of blindness. It is a multifactorial disease that is etiologically complex where elevated intraocular pressure in the eye is the major risk factor. Prostaglandin analogues are the first-line drugs in today’s glaucoma therapy. These are 20 carbon atom naturally occurring fatty acid derivatives biosynthesized from arachidonic acid. They involve COX pathway where arachidonic acid interacts with COX in the presence of oxygen and heme and produces PGG2. It is a cyclic endoperoxide with very short half life and genera...
Source: Medicinal Chemistry Research - April 7, 2016 Category: Chemistry Source Type: research

Acute Corneal Toxicity of Combined Antiglaucoma Topical Eyedrops.
CONCLUSION: The corneal toxicity of latanoprost/timolol with 0.02% BAC is greater than that of travoprost/timolol with polyquaternium-1 and dorzolamide/timolol with 0.005% BAC. Latanoprost/timolol contains 0.02% BAC, which may be responsible for the corneal toxicity. PMID: 27002346 [PubMed - as supplied by publisher] (Source: Current Eye Research)
Source: Current Eye Research - March 22, 2016 Category: Opthalmology Authors: Mohamed YH, Uematsu M, Onizuka N, Ueki R, Inoue D, Fujikawa A, Sasaki H, Kitaoka T Tags: Curr Eye Res Source Type: research